

Author index*

A

- Agúndez JAG (see García-Martín et al). 2004;76:119-27
 Ahluwalia R (see Sparreboom et al). 2004;76:38-44
 Albaladejo P (see Charbit et al). 2004;76:359-64
 Allabi AC, Gala J-L, Horsmans Y, Babaoglu MO, Bozkurt A, Heusterspreute M, Yasar U. Functional impact of CYP2C9*5, CYP2C9*6, CYP2C9*8, and CYP2C9*11 in vivo among black Africans. 2004;76:113-8
 Allen F (see Dempsey et al). 2004;76:64-72
 Åsberg A (see Hermann et al). 2004;76:388-91 (Letter)
 Aslanis V (see Joel et al). 2004;76:45-54
 Atkins G (see Leslie et al). 2004;76:365-70

B

- Babaoglu MO (see Allabi et al). 2004;76:113-8
 Backman JT (see Granfors et al). 2004;76:598-606
 Backman JT (see Niemi et al). 2004;76:239-49
 Bailey DG (see Goosen et al). 2004;76:607-17
 Balk AHMM (see Hesselink et al). 2004;76:545-56
 Banuvar S (see Booth et al). 2004;76:511-6 (Commentary)
 Batchelder AL (see Qiu et al). 2004;76:270-80
 Bauer S (see Kirchheiner et al). 2004;76:302-12
 Bauer S (see Mai et al). 2004;76:330-40
 Baumann P (see Benmebarek et al). 2004;76:55-63
 Baumer M (see Dishy et al). 2004;76:281-6
 Beal SL (see Soy et al). 2004;76:441-51
 Bebia Z, Buch SC, Wilson JW, Frye RF, Romkes M, Cecchetti A, Chaves-Gnecco D, Branch RA. Bioequivalence revisited: influence of age and sex on CYP enzymes. 2004;76:618-27
 Beitelshes AL (see Johnson et al). 2004;76:186 (Letter reply)
 Beitelshes AL (see Zineh et al). 2004;76:536-44
 Bellott R (see Charasson et al). 2004;76:528-35
 Benjamin N (see Zacharowski et al). 2004;76:350-8
 Benmebarek M, Devaud C, Gex-Fabry M, Golay KP, Brogli C, Baumann P, Gravier B, Eap CB. Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone. 2004;76:55-63
 Benowitz NL (see Dempsey et al). 2004;76:64-72
 Bergk V, Gasse C, Rothenbacher D, Loew M, Brenner H, Haefeli WE. Drug interactions in primary care: impact of a new algorithm on risk determination. 2004;76:85-96
 Blandizzi C, Danesi R, De Paolis B, Di Paolo A, Colucci R, Del Tacca M, Falcone A. Inhibition of acetylcholinesterase in patients receiving irinotecan (camptothecin-11). 2004;76:507-8 (Letter reply)
 Blaschke TF, Giacomini KM, Lewis B, Sheiner. 1940-2004. 2004;76:650-1 (Obituary)
 Boezen M (see Plasschaert et al). 2004;76:220-9
 Booth NL, Nikolic D, van Breemen RB, Geller SE, Banuvar S, Shulman LP, Farnsworth NR. Confusion regarding anticoagulant coumarins in dietary supplements. 2004;76:511-6 (Commentary)
 Bourbeau M (see van Heeswijk et al). 2004;76:588-97
 Bouvier ME (see Qiu et al). 2004;76:270-80
 Bozkurt A (see Allabi et al). 2004;76:113-8
 Branch RA (see Bebia et al). 2004;76:618-27
 Brenner H (see Bergk et al). 2004;76:85-96
 Brockmüller J (see Kirchheiner et al). 2004;76:302-12
 Brockmüller J (see Vormfelde et al). 2004;76:557-66
 Brogli C (see Benmebarek et al). 2004;76:55-63
 Brown CDA (see Simonson et al). 2004;76:167-77

- Brown NJ (see Pretorius et al). 2004;76:379-87
 Buch SC (see Bebia et al). 2004;76:618-27
 Budde K (see Mai et al). 2004;76:330-40
 Bugat R (see Léger et al). 2004;76:567-78
 Bührmann S (see Mitchell et al). 2004;76:396-408
 Burhenne J (see Ding et al). 2004;76:73-84

C

- Cameron DW (see van Heeswijk et al). 2004;76:588-97
 Carrier J (see Gurley et al). 2004;76:428-40
 Cascorbi I (see Giessmann et al). 2004;76:192-200
 Cecchetti A (see Bebia et al). 2004;76:618-27
 Charasson V, Bellott R, Meynard D, Longy M, Gorry P, Robert J. Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38. 2004;76:528-35
 Charbit B, Funck-Brentano C, Samain E, Jannier-Guillou V, Albaladejo P, Marty J. QT interval prolongation after oxytocin bolus during surgical induced abortion. 2004;76:359-64
 Chatelut E (see Joel et al). 2004;76:45-54
 Chatelut E (see Léger et al). 2004;76:567-78
 Chaves-Gnecco D (see Bebia et al). 2004;76:618-27
 Cho J-Y (see Yi et al). 2004;76:418-27
 Cho J-Y (see Yu et al). 2004;76:104-12
 Christensen H (see Hermann et al). 2004;76:388-91 (Letter)
 Chung J-Y (see Yi et al). 2004;76:418-27
 Chung J-Y (see Yu et al). 2004;76:104-12
 Cillie D (see Goosen et al). 2004;76:607-17
 Clarke S (see Tobin et al). 2004;76:505-6 (Letter)
 Cohen L (see Goosen et al). 2004;76:607-17
 Cole SL (see Qiu et al). 2004;76:270-80
 Colucci R (see Blandizzi et al). 2004;76:507-8 (Letter reply)
 Conemans J (see Schalekamp et al). 2004;76:409-17

D

- Danesi R (see Blandizzi et al). 2004;76:507-8 (Letter reply)
 Davis T (see Joel et al). 2004;76:45-54
 Dazert P (see Giessmann et al). 2004;76:192-200
 de Boer A (see Schalekamp et al). 2004;76:409-17
 de Bont ESJM (see Plasschaert et al). 2004;76:220-9
 de Graaf SS (see Plasschaert et al). 2004;76:220-9
 Del Soldato P (see Zacharowski et al). 2004;76:350-8
 Del Tacca M (see Blandizzi et al). 2004;76:507-8 (Letter reply)
 Dempsey D, Tutka P, Jacob P III, Allen F, Schoedel K, Tyndale RF, Benowitz NL. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. 2004;76:64-72
 De Paolis B (see Blandizzi et al). 2004;76:507-8 (Letter reply)
 De Smet PAGM. Health risks of herbal remedies: an update. 2004;76:1-17
 Devaud C (see Benmebarek et al). 2004;76:55-63
 de Vries EGE (see Plasschaert et al). 2004;76:220-9
 Dijkstra HP (see Goosen et al). 2004;76:607-17
 Di Marco F (see Guazzi et al). 2004;76:371-8
 Ding R, Tayrouz Y, Riedel K-D, Burhenne J, Weiss J, Mikus G, Haefeli WE. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. 2004;76:73-84
 Di Paolo A (see Blandizzi et al). 2004;76:507-8 (Letter reply)
 Dishy V, Pour MC, Feldman L, Naftali T, Baumer M, Efrati S, Golik A, Horne T, Weissgarten J. The effect of sildenafil on gastric emptying in patients with end-stage renal failure and symptoms of gastroparesis. 2004;76:281-6
 Doki K (see Momo et al). 2004;76:509-10 (Letter)
 Donnellan C (see Zacharowski et al). 2004;76:350-8
 Drescher S (see Glaeser et al). 2004;76:230-8

*July, pp. 1-98; August, pp. 99-188; September, pp. 189-286; October, pp. 287-392; November, pp. 393-510; December, pp. 511-682. Index to the ASCPT meeting abstracts is located in the February issue.

E

- Eap CB (see Benmebarek et al). 2004;76:55-63
 Eberst K (see Zineh et al). 2004;76:536-44
 Edwards DJ (see Gurley et al). 2004;76:428-40
 Efrati S (see Dishy et al). 2004;76:281-6
 Egorin MJ (see Frye et al). 2004;76:323-9
 Eichelbaum M (see Glaeser et al). 2004;76:230-8
 Eichelbaum M (see Raimundo et al). 2004;76:128-38
 Engelhardt S (see Vormfelde et al). 2004;76:557-66

F

- Faber MS, Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. 2004;76:178-84
 Falcone A (see Blandizzi et al). 2004;76:507-8 (Letter reply)
 Farnsworth NR (see Booth et al). 2004;76:511-6 (Commentary)
 Feldman L (see Dishy et al). 2004;76:281-6
 Fischer J (see Raimundo et al). 2004;76:128-38
 Fitzgerald SM (see Frye et al). 2004;76:323-9
 Flockhart DA (see Le Corre et al). 2004;76:139-53
 Forte P (see Zacharowski et al). 2004;76:350-8
 Frank B (see Mai et al). 2004;76:330-40
 Frias J (see García-Martín et al). 2004;76:119-27
 Fromm MF (see Glaeser et al). 2004;76:230-8
 Frye RF, Fitzgerald SM, Lagattuta TF, Hruska MW, Egorin MJ. Effect of St John's wort on imatinib mesylate pharmacokinetics. 2004;76:323-9
 Frye RF (see Bebia et al). 2004;76:618-27
 Fuhr U (see Faber and Fuhr). 2004;76:178-84
 Fujiki Y (see Fukami et al). 2004;76:519-27
 Fukami T, Nakajima M, Yoshida R, Tsuchiya Y, Fujiki Y, Katoh M, McLeod HL, Yokoi T. A novel polymorphism of human *CYP2A6* gene *CYP2A6*17* has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo. 2004;76:519-27
 Funck-Brentano C (see Charbit et al). 2004;76:359-64
 Furuta T (see Sugimoto et al). 2004;76:290-301

G

- Gaedigk A (see Zineh et al). 2004;76:536-44
 Gala J-L (see Allabi et al). 2004;76:113-8
 Galliciano KD (see van Heeswijk et al). 2004;76:588-97
 García-Martín E, Martínez C, Tabarés B, Frias J, Agúndez JAG. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. 2004;76:119-27
 Gardner SF (see Gurley et al). 2004;76:428-40
 Gasse C (see Bergk et al). 2004;76:85-96
 Gelderblom H (see Sparreboom et al). 2004;76:38-44
 Gelfand CA (see Zineh et al). 2004;76:536-44
 Geller SE (see Booth et al). 2004;76:511-6 (Commentary)
 Gentry WB (see Gurley et al). 2004;76:428-40
 Gex-Fabry M (see Benmebarek et al). 2004;76:55-63
 Giacomini KM (see Blaschke and Giacomini). 2004;76:650-1 (Obituary)
 Giessmann T, May K, Modess C, Wegner D, Hecker U, Zschiesche M, Dazert P, Grube M, Schroeder E, Warzok R, Cascorbi I, Kroemer HK, Siegmund W. Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. 2004;76:192-200
 Glaeser H, Drescher S, Hofmann U, Heinkele G, Somogyi AA, Eichelbaum M, Fromm MF. Impact of concentration and rate of intraluminal drug delivery on absorption and gut wall metabolism of verapamil in humans. 2004;76:230-8
 Goffinet M (see Léger et al). 2004;76:567-78
 Goh BC (see Zhao et al). 2004;76:210-9
 Golay KP (see Benmebarek et al). 2004;76:55-63
 Goldammer M (see Kirchheiner et al). 2004;76:302-12
 Goldstein DS (see Schroeder et al). 2004;76:480-9
 Golik A (see Dishy et al). 2004;76:281-6
 Goosen TC, Cillie D, Bailey DG, Yu C, He K, Hollenberg PF, Woster PM, Cohen L, Williams JA, Rheeders M, Dijkstra HP. Bergamottin contribution

- to the grapefruit juice-felodipine interaction and disposition in humans. 2004;76:607-17
 Gorry P (see Charasson et al). 2004;76:528-35
 Granfors MT, Backman JT, Neuvonen M, Neuvonen PJ. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. 2004;76:598-606
 Gravier B (see Benmebarek et al). 2004;76:55-63
 Greenblatt DJ, Harmatz JS, von Moltke LL, Wright CE, Shader RI. Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate. 2004;76:467-79
 Greenspan DL (see Winter et al). 2004;76:313-22
 Greenspan DL (see Winter et al). 2004;76:579-87
 Griese E-U (see Raimundo et al). 2004;76:128-38
 Griffin MR, Stein CM, Ray WA. Postmarketing surveillance for drug safety. 2004;76:504-5 (Letter reply)
 Groninger E (see Plasschaert et al). 2004;76:220-9
 Grube M (see Giessmann et al). 2004;76:192-200
 Guazzi M, Tumminello G, Di Marco F, Guazzi MD. Influences of sildenafil on lung function and hemodynamics in patients with chronic heart failure. 2004;76:371-8
 Guazzi MD (see Guazzi et al). 2004;76:371-8
 Guo J-Y (see Zhao et al). 2004;76:210-9
 Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Carrier J, Khan IA, Edwards DJ, Shah A. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: *Citrus aurantium*, *Echinacea purpurea*, milk thistle, and saw palmetto. 2004;76:428-40

H

- Haefeli WE (see Bergk et al). 2004;76:85-96
 Haefeli WE (see Ding et al). 2004;76:73-84
 Haertter S (see Schroeder et al). 2004;76:480-9
 Haller CA. St John's wort, depression, and catecholamines. 2004;76:393-5 (Commentary)
 Harmatz JS (see Greenblatt et al). 2004;76:467-79
 Hartmann A (see Hermann et al). 2004;76:388-91 (Letter)
 He K (see Goosen et al). 2004;76:607-17
 Hecker U (see Giessmann et al). 2004;76:192-200
 Heesch C (see Kirchheiner et al). 2004;76:302-12
 Heinkele G (see Glaeser et al). 2004;76:230-8
 Hermann M, Åsberg A, Christensen H, Holdaas H, Hartmann A, Reubsæet JLE. Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients. 2004;76:388-91 (Letter)
 Hermans M (see Schalkkamp et al). 2004;76:409-17
 Hesselink DA, van Gelder T, van Schaik RHN, Balk AHMM, van der Heiden IP, van Dam T, van der Werf M, Weimar W, Mathot RAA. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the *MDR-1*, and *CYP3A4*, and *CYP3A5* genes. 2004;76:545-56
 Heusterspreute M (see Allabi et al). 2004;76:113-8
 Hiraoka H (see Takizawa et al). 2004;76:648-9 (Letter)
 Hishida A (see Sugimoto et al). 2004;76:290-301
 Ho H (see Le Corre et al). 2004;76:139-53
 Hoffer C (see Kharasch et al). 2004;76:250-69
 Hoffer C (see Kharasch et al). 2004;76:452-66
 Hofmann U (see Glaeser et al). 2004;76:230-8
 Holdaas H (see Hermann et al). 2004;76:388-91 (Letter)
 Holden WL, Scarazzini LJ. Postmarketing surveillance for drug safety. 2004;76:503 (Letter)
 Hollenberg PF (see Goosen et al). 2004;76:607-17
 Homma M (see Momo et al). 2004;76:509-10 (Letter)
 Hong K-S (see Yi et al). 2004;76:418-27
 Hong K-S (see Yu et al). 2004;76:104-12
 Hooton TM (see Winter et al). 2004;76:313-22
 Hooton TM (see Winter et al). 2004;76:579-87
 Horiuchi R (see Takizawa et al). 2004;76:648-9 (Letter)
 Horne T (see Dishy et al). 2004;76:281-6
 Horsmans Y (see Allabi et al). 2004;76:113-8
 Hosono H (see Momo et al). 2004;76:509-10 (Letter)

Hruska MW (see Frye et al). 2004;76:323-9
Huang W (see Moody et al). 2004;76:154-66
Hubbard MA (see Gurley et al). 2004;76:428-40

I

Innocenti F, Undevia SD, Ramírez J, Mani S, Schilsky RL, Vogelzang NJ, Prado M, Ratain MJ. A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital. 2004;76:490-502
Insel PA (see Le Corre et al). 2004;76:139-53
Ishizaki T (see Sugimoto et al). 2004;76:290-301

J

Jacob P III (see Dempsey et al). 2004;76:64-72
Jacobson M (see Winter et al). 2004;76:313-22
Jacobson M (see Winter et al). 2004;76:579-87
Jang I-J (see Yi et al). 2004;76:418-27
Jang I-J (see Yu et al). 2004;76:104-12
Jannier-Guillou V (see Charbit et al). 2004;76:359-64
Jarcho JA (see Simonson et al). 2004;76:167-77
Joel S, Seymour M. Tumor-based pharmacokinetics has greater significance for anticancer drugs than does blood-based pharmacokinetics. 2004;76:508-9 (Letter reply)
Joel SP, Papamichael D, Richards F, Davis T, Aslanis V, Chatelut E, Locke K, Stevin ML, Seymour MT. Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. 2004;76:45-54
Johne A (see Mai et al). 2004;76:330-40
Johnson JA, Langae TY, Zineh I, Beitelshes AL. Caution with β_1 -adrenergic receptor genotyping. 2004;76:186 (Letter reply)
Johnson JA (see Zineh et al). 2004;76:536-44
Johnston A (see Zacharowski et al). 2004;76:350-8
Jordan J (see Schroeder et al). 2004;76:480-9
Jung H-R (see Yi et al). 2004;76:418-27
Jusko WJ (see Lima et al). 2004;76:27-37

K

Kailasam MT (see Le Corre et al). 2004;76:139-53
Kajimura M (see Sugimoto et al). 2004;76:290-301
Kamps WA (see Plasschaert et al). 2004;76:220-9
Katoh M (see Fukami et al). 2004;76:519-27
Kema I (see Plasschaert et al). 2004;76:220-9
Kennedy BP (see Le Corre et al). 2004;76:139-53
Khaliq Y (see van Heeswijk et al). 2004;76:588-97
Khan IA (see Gurley et al). 2004;76:428-40
Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and mitotic effects of methadone. 2004;76:250-69
Kharasch ED, Walker A, Hoffer C, Sheffels P. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. 2004;76:452-66
Kim J-R (see Yi et al). 2004;76:418-27
Kim J-R (see Yu et al). 2004;76:104-12
Kirchheiner J, Heesch C, Bauer S, Meisel C, Seringer A, Goldammer M, Tzvetkov M, Meineke I, Roots I, Brockmüller J. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. 2004;76:302-12
Kirchheiner J (see Vormfelde et al). 2004;76:557-66
Kissoon N (see Lima et al). 2004;76:27-37
Klein K (see Raimundo et al). 2004;76:128-38
Klotz U (see Schwab et al). 2004;76:201-9
Kohda Y (see Momo et al). 2004;76:509-10 (Letter)
Kroemer HK (see Giessmann et al). 2004;76:192-200

L

Lagattuta TF (see Frye et al). 2004;76:323-9
Laine K (see Tirkkonen and Laine). 2004;76:639-47

Lanfeer DE, Marsh S, McLeod HL. Caution with β_1 -adrenergic receptor genotyping. 2004;76:185-6 (Letter)
Langae TY (see Johnson et al). 2004;76:186 (Letter reply)
Le Corre P, Parmer RJ, Kailasam MT, Kennedy BP, Skaar TP, Ho H, Leverage R, Smith DW, Ziegler MG, Insel PA, Schork NJ, Flockhart DA, O'Connor DT. Human sympathetic activation by α_2 -adrenergic blockade with yohimbine: bimodal, epistatic influence of cytochrome P450-mediated drug metabolism. 2004;76:139-53
Lee HS (see Zhao et al). 2004;76:210-9
Lee SC (see Zhao et al). 2004;76:210-9
Leeder JS (see Zineh et al). 2004;76:536-44
Léger F, Loos WJ, Bugat R, Mathijssen RHJ, Goffinet M, Verweij J, Sparreboom A, Chatelut E. Mechanism-based models for topotecan-induced neutropenia. 2004;76:567-78
Leslie SJ, Atkins G, Oliver JJ, Webb DJ. No adverse hemodynamic interaction between sildenafil and red wine. 2004;76:365-70
Leverge R (see Le Corre et al). 2004;76:139-53
Lim H-S (see Yi et al). 2004;76:418-27
Lim H-S (see Yu et al). 2004;76:104-12
Lim Y-T (see Zhao et al). 2004;76:210-9
Lima JJ, Matsushima N, Kissoon N, Wang J, Sylvester JE, Jusko WJ. Modeling the metabolic effects of terbutaline in β_2 -adrenergic receptor diplotypes. 2004;76:27-37
Liu K-H (see Yu et al). 2004;76:104-12
Liu T-C (see Zhao et al). 2004;76:210-9
Locke K (see Joel et al). 2004;76:45-54
Loew M (see Bergk et al). 2004;76:85-96
Loke C (see Zhao et al). 2004;76:210-9
Longy M (see Charasson et al). 2004;76:528-35
Loos WJ (see Léger et al). 2004;76:567-78
Lu W-L (see Zhao et al). 2004;76:210-9
Lückebergfeld B (see Mitchell et al). 2004;76:396-408
Luft FC (see Schroeder et al). 2004;76:480-9

M

Mai I, Bauer S, Perloff ES, John A, Uehleke B, Frank B, Budde K, Roots I. Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction. 2004;76:330-40
Mani S (see Innocenti et al). 2004;76:490-502
Marsh S (see Lanfeer et al). 2004;76:185-6 (Letter)
Marsh S (see Sparreboom et al). 2004;76:38-44
Martin PD (see Simonson et al). 2004;76:167-77
Martínez C (see García-Martín et al). 2004;76:119-27
Marty J (see Charbit et al). 2004;76:359-64
Masica AL, Mayo G, Wilkinson GR. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. 2004;76:341-9
Mathijssen RHJ (see Léger et al). 2004;76:567-78
Mathot RAA (see Hesselink et al). 2004;76:545-56
Matsushima N (see Lima et al). 2004;76:27-37
May K (see Giessmann et al). 2004;76:192-200
Mayo G (see Masica et al). 2004;76:341-9
McDonald GB (see Qiu et al). 2004;76:270-80
McFarlane JA (see Pretorius et al). 2004;76:379-87
McLeod HL (see Fukami et al). 2004;76:519-27
McLeod HL (see Lanfeer et al). 2004;76:185-6 (Letter)
McLeod HL (see Sparreboom et al). 2004;76:38-44
Meijerman I (see Schalekamp et al). 2004;76:409-17
Meineke I (see Kirchheiner et al). 2004;76:302-12
Meineke I (see Vormfelde et al). 2004;76:557-66
Meisel C (see Kirchheiner et al). 2004;76:302-12
Meynard D (see Charasson et al). 2004;76:528-35
Mikus G (see Ding et al). 2004;76:73-84
Mitchell A, Lückebergfeld B, Bührmann S, Rushentsova U, Nürnberger J, Siffert W, Schäfers RF, Philipp T, Wenzel RR. Effects of systemic endothelin A receptor antagonism in various vascular beds in men: in vivo interactions of the major blood pressure-regulating systems and associations with the *GNB3* C825 T polymorphism. 2004;76:396-408
Mitchell PD (see Simonson et al). 2004;76:167-77

- Modess C (see Giessmann et al). 2004;76:192-200
Momo K, Doki K, Hosono H, Homma M, Kohda Y. Drug interaction of tizanidine and fluvoxamine. 2004;76:509-10 (Letter)
Moody DE, Walsh SL, Rollins DE, Neff JA, Huang W. Ketoconazole, a cytochrome P450 3A4 inhibitor, markedly increases concentrations of levo-acetyl- α -methadol in opioid-naïve individuals. 2004;76:154-66
Murphey LJ (see Pretorius et al). 2004;76:379-87

N

- Naftali T (see Dishy et al). 2004;76:281-6
Nakajima M (see Fukami et al). 2004;76:519-27
Nakamura K (see Takizawa et al). 2004;76:648-9 (Letter)
Neff JA (see Moody et al). 2004;76:154-66
Neuvonen M (see Granfors et al). 2004;76:598-606
Neuvonen PJ (see Granfors et al). 2004;76:598-606
Neuvonen PJ (see Niemi et al). 2004;76:239-49
Nichol JL (see Wang et al). 2004;76:628-38
Niemi M, Backman JT, Neuvonen PJ. Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. 2004;76:239-49
Nikolic D (see Booth et al). 2004;76:511-6 (Commentary)
Nünberger J (see Mitchell et al). 2004;76:396-408

O

- Obach R (see Sparreboom et al). 2004;76:38-44
O'Byrne S (see Zacharowski et al). 2004;76:350-8
O'Connor DT (see Le Corre et al). 2004;76:139-53
Oh D-S (see Yi et al). 2004;76:418-27
Oh D-S (see Yu et al). 2004;76:104-12
Ohashi K (see Sugimoto et al). 2004;76:290-301
Oliver JJ (see Leslie et al). 2004;76:365-70
Oosterhof M (see Schalekamp et al). 2004;76:409-17

P

- Papamichael D (see Joel et al). 2004;76:45-54
Parmer RJ (see Le Corre et al). 2004;76:139-53
Pauly DF (see Zineh et al). 2004;76:536-44
Perini JA (see Vianna-Jorge et al). 2004;76:18-26
Perloff ES (see Mai et al). 2004;76:330-40
Philipp T (see Mitchell et al). 2004;76:396-408
Phillips EJ (see van Heeswijk et al). 2004;76:588-97
Phillips MS (see Zineh et al). 2004;76:536-44
Plasschaert SLA, Groninger E, Boezen M, Kema I, de Vries EGE, Uges D, Veerman AJP, Kamps WA, Vellenga E, de Graaf SS, de Bont ESJM. Influence of functional polymorphisms of the *MDR1* gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. 2004;76:220-9
Pour MC (see Dishy et al). 2004;76:281-6
Prado M (see Innocenti et al). 2004;76:490-502
Present CA (see Wolf and Present). 2004;76:508 (Letter)
Pretorius M, McFarlane JA, Vaughan DE, Brown NJ, Murphey LJ. Angiotensin-converting enzyme inhibition and smoking potentiate the kinin response to cardiopulmonary bypass. 2004;76:379-87
Principe P (see Sparreboom et al). 2004;76:38-44

Q

- Qiu R, Yao A, Vicini P, McDonald GB, Batchelder AL, Bouvier ME, Cole SL, Slattery JT. Diminishing the risk of nonrelapse mortality in hematopoietic stem cell transplantation: prediction of exposure to the cyclophosphamide metabolite carboxyethylphosphoramide mustard. 2004;76:270-80

R

- Raimundo S, Toscano C, Klein K, Fischer J, Griese E-U, Eichelbaum M, Schwab M, Zanger UM. A novel intronic mutation, 2988GA, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. 2004;76:128-38

- Ramírez J (see Innocenti et al). 2004;76:490-502
Rankin SC (see Zhao et al). 2004;76:210-9
Ratain MJ (see Innocenti et al). 2004;76:490-502
Ray WA (see Griffin et al). 2004;76:504-5 (Letter reply)
Raza A (see Simonson et al). 2004;76:167-77
Reidenberg MM. Optimizing drug therapy. 2004;76:98 (Letter reply)
Reubsaet JLE (see Hermann et al). 2004;76:388-91 (Letter)
Rheeders M (see Goosen et al). 2004;76:607-17
Richards F (see Joel et al). 2004;76:45-54
Riedel K-D (see Ding et al). 2004;76:73-84
Rivory L (see Tobin et al). 2004;76:505-6 (Letter)
Robert J (see Charasson et al). 2004;76:528-35
Rollins DE (see Moody et al). 2004;76:154-66
Romkes M (see Bebia et al). 2004;76:618-27
Rondinelli E (see Vianna-Jorge et al). 2004;76:18-26
Roots I (see Kirchheiner et al). 2004;76:302-12
Roots I (see Mai et al). 2004;76:330-40
Rostami-Hodjegan A (see Yang et al). 2004;76:391 (Letter)
Rothenbacher D (see Bergk et al). 2004;76:85-96
Rushentsova U (see Mitchell et al). 2004;76:396-408

S

- Sakurai M (see Sugimoto et al). 2004;76:290-301
Samain E (see Charbit et al). 2004;76:359-64
Scarazzini LJ (see Holden and Scarazzini). 2004;76:503 (Letter)
Schaeffeler E (see Schwab et al). 2004;76:201-9
Schäfers RF (see Mitchell et al). 2004;76:396-408
Schalekamp T, Oosterhof M, van Meegen E, van Der Meer FJM, Conemans J, Hermans M, Meijerman I, de Boer A. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status. 2004;76:409-17
Schilsky RL (see Innocenti et al). 2004;76:490-502
Schneck DW (see Simonson et al). 2004;76:167-77
Schoedel K (see Dempsey et al). 2004;76:64-72
Schork NJ (see Le Corre et al). 2004;76:139-53
Schroeder C, Tank J, Goldstein DS, Stoeter M, Haertter S, Luft FC, Jordan J. Influence of St John's wort on catecholamine turnover and cardiovascular regulation in humans. 2004;76:480-9
Schroeder E (see Giessmann et al). 2004;76:192-200
Schwab M, Schaeffeler E, Klotz U, Treiber G. CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of *Helicobacter pylori*. 2004;76:201-9
Schwab M (see Raimundo et al). 2004;76:128-38
Seguin I (see van Heeswijk et al). 2004;76:588-97
Seinger A (see Kirchheiner et al). 2004;76:302-12
Seymour M (see Joel and Seymour). 2004;76:508-9 (Letter reply)
Seymour MT (see Joel et al). 2004;76:45-54
Shader RI (see Greenblatt et al). 2004;76:467-79
Shah A (see Gurley et al). 2004;76:428-40
Sheffels P (see Kharasch et al). 2004;76:250-69
Sheffels P (see Kharasch et al). 2004;76:452-66
Sheiner LB (see Soy et al). 2004;76:441-51
Shin J-G (see Yu et al). 2004;76:104-12
Shin S-G (see Yi et al). 2004;76:418-27
Shin S-G (see Yu et al). 2004;76:104-12
Shirai N (see Sugimoto et al). 2004;76:290-301
Shulman LP (see Booth et al). 2004;76:511-6 (Commentary)
Siegmond W (see Giessmann et al). 2004;76:192-200
Siffert W (see Mitchell et al). 2004;76:396-408
Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CDA, Windass AS, Schneck DW. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. 2004;76:167-77
Skaar TP (see Le Corre et al). 2004;76:139-53
Slattery JT (see Qiu et al). 2004;76:270-80
Slattery JT (see Winter et al). 2004;76:313-22
Slattery JT (see Winter et al). 2004;76:579-87
Slevin ML (see Joel et al). 2004;76:45-54
Smith DW (see Le Corre et al). 2004;76:139-53

- Somogyi AA (*see* Glaeser et al). 2004;76:230-8
Soy D, Beal SL, Sheiner LB. Population one-compartment pharmacokinetic analysis with missing dosage data. 2004;76:441-51
Sparreboom A, Gelderblom H, Marsh S, Ahluwalia R, Obach R, Principe P, Twelves C, Verweij J, McLeod HL. Diflomotecan pharmacokinetics in relation to ABCG2 421CA genotype. 2004;76:38-44
Sparreboom A (*see* Léger et al). 2004;76:567-78
Spector R. Optimizing drug therapy. 2004;76:97-8 (Letter)
Stein CM. Clinical Pharmacology & Therapeutics annual report 2003. 2004;76:189-91 (Commentary)
Stein CM. Publishing work sponsored by the tobacco industry. 2004;76:517-8 (Commentary)
Stein CM (*see* Griffin et al). 2004;76:504-5 (Letter reply)
Stoeter M (*see* Schroeder et al). 2004;76:480-9
Suarez-Kurtz G (*see* Vianna-Jorge et al). 2004;76:18-26
Sugimoto M, Furuta T, Shirai N, Kajimura M, Hishida A, Sakurai M, Ohashi K, Ishizaki T. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. 2004;76:290-301
Sullivan JT. A message from the ASCPT membership committee chairperson. 2004;76:187-8
Sullivan JT. A message from the ASCPT membership committee chairperson. 2004;76:392
Sullivan JT. A message from the ASCPT membership committee chairperson. 2004;76:652
Sullivan JT (*see* Wang et al). 2004;76:628-38
Sylvester JE (*see* Lima et al). 2004;76:27-37

T

- Tabarés B (*see* García-Martín et al). 2004;76:119-27
Takizawa D, Hiraoka H, Nakamura K, Yamamoto K, Horiuchi R. Propofol concentrations during the anhepatic phase of living-related donor liver transplantation. 2004;76:648-9 (Letter)
Tan T (*see* Zhao et al). 2004;76:210-9
Tank J (*see* Schroeder et al). 2004;76:480-9
Tayrouz Y (*see* Ding et al). 2004;76:73-84
Tirkkonen T, Laine K. Drug interactions with the potential to prevent prodrug activation as a common source of irrational prescribing in hospital inpatients. 2004;76:639-47
Tobin P, Rivory L, Clarke S. Inhibition of acetylcholinesterase in patients receiving irinotecan (camptothecin-11). 2004;76:505-6 (Letter)
Toscano C (*see* Raimundo et al). 2004;76:128-38
Trapnell CB (*see* Winter et al). 2004;76:313-22
Trapnell CB (*see* Winter et al). 2004;76:579-87
Treiber G (*see* Schwab et al). 2004;76:201-9
Tsuchiya Y (*see* Fukami et al). 2004;76:519-27
Tuchen F (*see* Vormfelde et al). 2004;76:557-66
Tucker GT (*see* Yang et al). 2004;76:391 (Letter)
Tumminello G (*see* Guazzi et al). 2004;76:371-8
Tutka P (*see* Dempsey et al). 2004;76:64-72
Twelves C (*see* Sparreboom et al). 2004;76:38-44
Tyndale RF (*see* Dempsey et al). 2004;76:64-72
Tzvetkov M (*see* Kirchheiner et al). 2004;76:302-12

U

- Uehleke B (*see* Mai et al). 2004;76:330-40
Uges D (*see* Plasschaert et al). 2004;76:220-9
Unadkat JD (*see* Winter et al). 2004;76:313-22
Unadkat JD (*see* Winter et al). 2004;76:579-87
Undevia SD (*see* Innocenti et al). 2004;76:490-502 V
van Breemen RB (*see* Booth et al). 2004;76:511-6 (Commentary)
van Dam T (*see* Hesselink et al). 2004;76:545-56
van der Heiden IP (*see* Hesselink et al). 2004;76:545-56
van Der Meer FJM (*see* Schalekamp et al). 2004;76:409-17
van der Werf M (*see* Hesselink et al). 2004;76:545-56
van Gelder T (*see* Hesselink et al). 2004;76:545-56

- van Heeswijk RPG, Khaliq Y, Gallicano KD, Bourbeau M, Seguin I, Phillips EJ, Cameron DW. The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum. 2004;76:588-97
van Meegen E (*see* Schalekamp et al). 2004;76:409-17
van Schaik RHN (*see* Hesselink et al). 2004;76:545-56
Vaughan DE (*see* Pretorius et al). 2004;76:379-87
Veerman AJP (*see* Plasschaert et al). 2004;76:220-9
Vellenga E (*see* Plasschaert et al). 2004;76:220-9
Verweij J (*see* Léger et al). 2004;76:567-78
Verweij J (*see* Sparreboom et al). 2004;76:38-44
Vianna-Jorge R, Perini JA, Rondinelli E, Suarez-Kurtz G. CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. 2004;76:18-26
Vicini P (*see* Qiu et al). 2004;76:270-80
Vogelzang NJ (*see* Innocenti et al). 2004;76:490-502
Vojnovic I (*see* Zacharowski et al). 2004;76:350-8
von Moltke LL (*see* Greenblatt et al). 2004;76:467-79
Vormfelde SV, Engelhardt S, Zirk A, Meineke I, Tuchen F, Kirchheiner J, Brockmüller J. CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. 2004;76:557-66

W

- Walker A (*see* Kharasch et al). 2004;76:452-66
Walker JR (*see* Zineh et al). 2004;76:536-44
Walsh SL (*see* Moody et al). 2004;76:154-66
Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. 2004;76:628-38
Wang J (*see* Lima et al). 2004;76:27-37
Warzok R (*see* Giessmann et al). 2004;76:192-200
Webb DJ (*see* Leslie et al). 2004;76:365-70
Wegner D (*see* Giessmann et al). 2004;76:192-200
Weimar W (*see* Hesselink et al). 2004;76:545-56
Weiss J (*see* Ding et al). 2004;76:73-84
Weissgarten J (*see* Dishy et al). 2004;76:281-6
Wenzel RR (*see* Mitchell et al). 2004;76:396-408
Whittington D (*see* Kharasch et al). 2004;76:250-69
Wilkinson GR. Genetic variability in cytochrome P450 3A5 and in vivo cytochrome P450 3A activity: some answers but still questions. 2004;76:99-103 (Commentary)
Wilkinson GR (*see* Masica et al). 2004;76:341-9
Williams DK (*see* Gurley et al). 2004;76:428-40
Williams JA (*see* Goosen et al). 2004;76:607-17
Wilson JW (*see* Bebia et al). 2004;76:618-27
Windass AS (*see* Simonson et al). 2004;76:167-77
Winter HR, Trapnell CB, Slattery JT, Jacobson M, Greenspan DL, Hooton TM, Unadkat JD. The effect of clarithromycin, fluconazole, and rifabutin on dapsone hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283). 2004;76:579-87
Winter HR, Trapnell CB, Slattery JT, Jacobson M, Greenspan DL, Hooton TM, Unadkat JD. The effect of clarithromycin, fluconazole, and rifabutin on sulfamethoxazole hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283). 2004;76:313-22
Wolf W, Presant CA. Tumor-based pharmacokinetics has greater significance for anticancer drugs than does blood-based pharmacokinetics. 2004;76:508 (Letter)
Woosley RL. Discovering adverse reactions: why does it take so long? 2004;76:287-9 (Commentary)
Woster PM (*see* Goosen et al). 2004;76:607-17
Wright CE (*see* Greenblatt et al). 2004;76:467-79
Wu TS (*see* Zhao et al). 2004;76:210-9

Y

- Yamamoto K (*see* Takizawa et al). 2004;76:648-9 (Letter)
Yang J, Tucker GT, Rostami-Hodjegan A. Cytochrome P450 3A expression and activity in the human small intestine. 2004;76:391 (Letter)
Yao A (*see* Qiu et al). 2004;76:270-80
Yasar U (*see* Allabi et al). 2004;76:113-8

- Yi S-Y, Hong K-S, Lim H-S, Chung J-Y, Oh D-S, Kim J-R, Jung H-R, Cho J-Y, Yu K-S, Jang I-J, Shin S-G. A variant 2677A allele of the *MDR1* gene affects fexofenadine disposition. 2004;76:418-27
- Yi S-Y (see Yu et al). 2004;76:104-12
- Yokoi T (see Fukami et al). 2004;76:519-27
- Yoshida R (see Fukami et al). 2004;76:519-27
- Yu C (see Goosen et al). 2004;76:607-17
- Yu K-S, Cho J-Y, Jang I-J, Hong K-S, Chung J-Y, Kim J-R, Lim H-S, Oh D-S, Yi S-Y, Liu K-H, Shin J-G, Shin S-G. Effect of the *CYP3A5* genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. 2004;76:104-12
- Yu K-S (see Yi et al). 2004;76:418-27

Z

- Zacharowski K (see Zacharowski et al). 2004;76:350-8

- Zacharowski P, Zacharowski K, Donnellan C, Johnston A, Vojnovic I, Forte P, Del Soldato P, Benjamin N, O'Byrne S. The effects of metabolic fate of nitrofuribuprofen in healthy volunteers. 2004;76:350-8
- Zanger UM (see Raimundo et al). 2004;76:128-38
- Zhang Q (see Zhao et al). 2004;76:210-9
- Zhao F, Loke C, Rankin SC, Guo J-Y, Lee HS, Wu TS, Tan T, Liu T-C, Lu W-L, Lim Y-T, Zhang Q, Goh BC, Lee SC. Novel *CYP2C9* genetic variants in Asian subjects and their influence on maintenance warfarin dose. 2004;76:210-9
- Ziegler MG (see Le Corre et al). 2004;76:139-53
- Zineh I, Beitelshees AL, Gaedigk A, Walker JR, Pauly DF, Eberst K, Leeder JS, Phillips MS, Gelfand CA, Johnson JA. Pharmacokinetics and *CYP2D6* genotypes do not predict metoprolol adverse events or efficacy in hypertension. 2004;76:536-44
- Zineh I (see Johnson et al). 2004;76:186 (Letter reply)
- Zirk A (see Vormfelde et al). 2004;76:557-66
- Zschesche M (see Giessmann et al). 2004;76:192-200

Subject index*

A

Abortion

QT interval prolongation after oxytocin bolus during surgical induced abortion (Charbit et al). 2004;76:359-64

Acetylcholinesterase inhibitors

Inhibition of acetylcholinesterase in patients receiving irinotecan (camptothecin-11) (Tobin et al) (Letter); (Blandizzi et al) (Reply). 2004;76:505-8

Acute lymphoblastic leukemia; *see* Leukemia, lymphocytic, acute

Administration, oral

Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis (Kharasch et al). 2004;76:452-66

Adrenergic alpha receptor blockers

Human sympathetic activation by α_2 -adrenergic blockade with yohimbine: bimodal, epistatic influence of cytochrome P450-mediated drug metabolism (Le Corre et al). 2004;76:139-53

Adrenergic beta receptor blockers

Caution with β_1 -adrenergic receptor genotyping (Lanfear et al) (Letter); (Johnson et al) (Reply). 2004;76:185-6

Adverse effects

Discovering adverse reactions: why does it take so long? (Woosley). 2004;76:287-9 (Commentary)

African Americans

Functional impact of *CYP2C9*5*, *CYP2C9*6*, *CYP2C9*8*, and *CYP2C9*11* in vivo among black Africans (Allabi et al). 2004;76:113-8

Age factors

Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate (Greenblatt et al). 2004;76:467-79

Bioequivalence revisited: influence of age and sex on CYP enzymes (Behia et al). 2004;76:618-27

Alcohol drinking

No adverse hemodynamic interaction between sildenafil and red wine (Leslie et al). 2004;76:365-70

Algorithms

Drug interactions in primary care: impact of a new algorithm on risk determination (Bergk et al). 2004;76:85-96

Alleles

A variant 2677A allele of the *MDR1* gene affects fexofenadine disposition (Yi et al). 2004;76:418-27

Alprazolam

In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam (Masica et al). 2004;76:341-9

American Society for Clinical Pharmacology and Therapeutics

A message from the ASCPT Membership Committee chairperson (Sullivan). 2004;76:187-8, 2004;76:392

A message from the ASCPT membership committee chairperson (Sullivan). 2004;76:652

AMG 531

Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand (Wang et al). 2004;76:628-38

*July, pp. 1-98; August, pp. 99-188; September, pp. 189-286; October, pp. 287-392; November, pp. 393-510; December, pp. 511-682. Index to the ASCPT meeting abstracts is located in the February issue.

Amino acids

Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms (García-Martín et al). 2004;76:119-27

A novel polymorphism of human *CYP2A6* gene *CYP2A6*17* has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo (Fukami et al). 2004;76:519-27

Angiotensin converting enzyme; *see* Kininase II

Anticoagulants

Confusion regarding anticoagulant coumarins in dietary supplements (Booth et al). 2004;76:511-6 (Commentary)

Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status (Schalekamp et al). 2004;76:409-17

Antidepressive agents

Influence of St John's wort on catecholamine turnover and cardiovascular regulation in humans (Schroeder et al). 2004;76:480-9

St John's wort, depression, and catecholamines (Haller). 2004;76:393-5 (Commentary)

Antineoplastic agents

Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38 (Charasson et al). 2004;76:528-35

A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital (Innocenti et al). 2004;76:490-502

Tumor-based pharmacokinetics has greater significance for anticancer drugs than does blood-based pharmacokinetics (Wolf and Presant) (Letter); (Joel and Seymour) (Reply). 2004;76:508-9

Antirejection therapy; *see* Immunosuppression

Asia

Novel *CYP2C9* genetic variants in Asian subjects and their influence on maintenance warfarin dose (Zhao et al). 2004;76:210-9

Atorvastatin

Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients (Hermann et al). 2004;76:388-91 (Letter)

B

Bergamottin

Bergamottin contribution to the grapefruit juice-felodipine interaction and disposition in humans (Goosen et al). 2004;76:607-17

Beta adrenergic receptors; *see* Receptors, adrenergic, beta

Beverages

Bergamottin contribution to the grapefruit juice-felodipine interaction and disposition in humans (Goosen et al). 2004;76:607-17

Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone (Benmebarek et al). 2004;76:55-63

No adverse hemodynamic interaction between sildenafil and red wine (Leslie et al). 2004;76:365-70

Bioequivalence; *see* Therapeutic equivalency

Blood

Tumor-based pharmacokinetics has greater significance for anticancer drugs than does blood-based pharmacokinetics (Wolf and Presant) (Letter); (Joel and Seymour) (Reply). 2004;76:508-9

Blood pressure

Effects of systemic endothelin A receptor antagonism in various vascular beds in men: in vivo interactions of the major blood pressure-regulating systems and associations with the *GNB3* C825 T polymorphism (Mitchell et al). 2004;76:396-408

Brazil

CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians (Vianna-Jorge et al). 2004;76:18-26

Breast neoplasms

Diflomotecan pharmacokinetics in relation to *ABCG2* 421CA genotype (Sparreboom et al). 2004;76:38-44

C**Camptothecin**

Inhibition of acetylcholinesterase in patients receiving irinotecan (camptothecin-11) (Tobin et al) (Letter); (Blandizzi et al) (Reply). 2004;76:505-8

Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38 (Charasson et al). 2004;76:528-35

Carbamazepine

Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans (Giessmann et al). 2004;76:192-200

Carboxyethylphosphoramide mustard

Diminishing the risk of nonrelapse mortality in hematopoietic stem cell transplantation: prediction of exposure to the cyclophosphamide metabolite carboxyethylphosphoramide mustard (Qiu et al). 2004;76:270-80

Carboxylic ester hydrolases

Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38 (Charasson et al). 2004;76:528-35

Cardiopulmonary bypass

Angiotensin-converting enzyme inhibition and smoking potentiate the kinetic response to cardiopulmonary bypass (Pretorius et al). 2004;76:379-87

Cardiovascular system

Influence of St John's wort on catecholamine turnover and cardiovascular regulation in humans (Schroeder et al). 2004;76:480-9

Catecholamines

Influence of St John's wort on catecholamine turnover and cardiovascular regulation in humans (Schroeder et al). 2004;76:480-9

St John's wort, depression, and catecholamines (Haller). 2004;76:393-5 (Commentary)

Cessation of smoking; see Smoking cessation**Ciprofloxacin**

Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism (Granfors et al). 2004;76:598-606

Cisplatin

Mechanism-based models for topotecan-induced neutropenia (Léger et al). 2004;76:567-78

Citrus aurantium

In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: *Citrus aurantium*, *Echinacea purpurea*, milk thistle, and saw palmetto (Gurley et al). 2004;76:428-40

Clarithromycin

The effect of clarithromycin, fluconazole, and rifabutin on dapsone hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283) (Winter et al). 2004;76:579-87

The effect of clarithromycin, fluconazole, and rifabutin on sulfamethoxazole hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283) (Winter et al). 2004;76:313-22

Clinical Pharmacology & Therapeutics

Clinical Pharmacology & Therapeutics annual report 2003 (Stein). 2004;76:189-91 (Commentary)

Clozapine

Time response of cytochrome P450 1A2 activity on cessation of heavy smoking (Faber and Fuhr). 2004;76:178-84

Colorectal neoplasms

Inhibition of acetylcholinesterase in patients receiving irinotecan (camptothecin-11) (Tobin et al) (Letter); (Blandizzi et al) (Reply). 2004;76:505-8

Commentaries

Commentaries. 2004;76:99-103, 189-91, 287-9, 393-5, 511-8

Correspondence; see Letters to the editor**Costs and cost analysis**

Optimizing drug therapy (Spector) (Letter); (Reidenberg) (Reply). 2004;76:97-8

Coumarins

Confusion regarding anticoagulant coumarins in dietary supplements (Booth et al). 2004;76:511-6 (Commentary)

A novel polymorphism of human *CYP2A6* gene *CYP2A6*17* has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo (Fukami et al). 2004;76:519-27

Cyclophosphamide

Diminishing the risk of nonrelapse mortality in hematopoietic stem cell transplantation: prediction of exposure to the cyclophosphamide metabolite carboxyethylphosphoramide mustard (Qiu et al). 2004;76:270-80

Cyclosporine

Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction (Mai et al). 2004;76:330-40

A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital (Innocenti et al). 2004;76:490-502

Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the *MDR-1*, and *CYP3A4*, and *CYP3A5* genes (Hesselink et al). 2004;76:545-56

Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine (Simonson et al). 2004;76:167-77

Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients (Hermann et al). 2004;76:388-91 (Letter)

Cytochrome P450

Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate (Greenblatt et al). 2004;76:467-79

Bioequivalence revisited: influence of age and sex on CYP enzymes (Bebia et al). 2004;76:618-27

Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism (Granfors et al). 2004;76:598-606

CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians (Vianna-Jorge et al). 2004;76:18-26

CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide (Vormfelde et al). 2004;76:557-66

CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of *Helicobacter pylori* (Schwab et al). 2004;76:201-9

Cytochrome P450 3A expression and activity in the human small intestine (Yang et al). 2004;76:391 (Letter)

Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status (Sugimoto et al). 2004;76:290-301

Effect of the *CYP3A5* genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states (Yu et al). 2004;76:104-12

Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status (Schalekamp et al). 2004;76:409-17

Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone (Niemi et al). 2004;76:239-49

Functional impact of *CYP2C9*5*, *CYP2C9*6*, *CYP2C9*8*, and

- CYP2C9*11* in vivo among black Africans (Allabi et al). 2004;76:113-8
- Genetic variability in cytochrome P450 3A5 and in vivo cytochrome P450 3A activity: some answers but still questions (Wilkinson). 2004;76:99-103 (Commentary)
- Human sympathetic activation by α_2 -adrenergic blockade with yohimbine: bimodal, epistatic influence of cytochrome P450-mediated drug metabolism (Le Corre et al). 2004;76:139-53
- In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: *Citrus aurantium*, *Echinacea purpurea*, milk thistle, and saw palmetto (Gurley et al). 2004;76:428-40
- In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam (Masica et al). 2004;76:341-9
- Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics (Kirchheiner et al). 2004;76:302-12
- Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms (García-Martín et al). 2004;76:119-27
- Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis (Kharasch et al). 2004;76:452-66
- Ketoconazole, a cytochrome P450 3A4 inhibitor, markedly increases concentrations of levo-acetyl- α -methadol in opioid-naïve individuals (Moody et al). 2004;76:154-66
- Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity (Dempsey et al). 2004;76:64-72
- Novel *CYP2C9* genetic variants in Asian subjects and their influence on maintenance warfarin dose (Zhao et al). 2004;76:210-9
- A novel intronic mutation, 2988GA, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects (Raimundo et al). 2004;76:128-38
- A novel polymorphism of human *CYP2A6* gene *CYP2A6*17* has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo (Fukami et al). 2004;76:519-27
- Pharmacokinetics and *CYP2D6* genotypes do not predict metoprolol adverse events or efficacy in hypertension (Zineh et al). 2004;76:536-44
- Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the *MDR-1*, and *CYP3A4*, and *CYP3A5* genes (Hesselink et al). 2004;76:545-56
- Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and mitotic effects of methadone (Kharasch et al). 2004;76:250-69
- Time response of cytochrome P450 1A2 activity on cessation of heavy smoking (Faber and Fuhr). 2004;76:178-84

D

Dapsone

- The effect of clarithromycin, fluconazole, and rifabutin on dapsone hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283) (Winter et al). 2004;76:579-87

Depression

- St John's wort, depression, and catecholamines (Haller). 2004;76:393-5 (Commentary)

Dietary supplements; see Medicine, herbal

Diffamotecan

- Diffamotecan pharmacokinetics in relation to *ABCG2* 421CA genotype (Sparreboom et al). 2004;76:38-44

Digestive system abnormalities

- The effect of sildenafil on gastric emptying in patients with end-stage renal failure and symptoms of gastroparesis (Dishy et al). 2004;76:281-6

Digitalis glycosides

- Optimizing drug therapy (Spector) (Letter); (Reidenberg) (Reply). 2004;76:97-8

Digoxin

- Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers (Ding et al). 2004;76:73-84

Diuretics

- CYP2C9* polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide (Vormfelde et al). 2004;76:557-66

Dose-response relationship, drug

- Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status (Sugimoto et al). 2004;76:290-301
- Population one-compartment pharmacokinetic analysis with missing dosage data (Soy et al). 2004;76:441-51

Drug delivery systems

- Impact of concentration and rate of intraluminal drug delivery on absorption and gut wall metabolism of verapamil in humans (Glaeser et al). 2004;76:230-8

Drug interactions

- Bergamottin contribution to the grapefruit juice-felodipine interaction and disposition in humans (Goosen et al). 2004;76:607-17
- Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism (Granfors et al). 2004;76:598-606
- Discovering adverse reactions: why does it take so long? (Woosley). 2004;76:287-9 (Commentary)
- Drug interaction of tizanidine and fluvoxamine (Momo et al). 2004;76:509-10 (Letter)
- Drug interactions with the potential to prevent prodrug activation as a common source of irrational prescribing in hospital inpatients (Tirkkonen and Laine). 2004;76:639-47
- Drug interactions in primary care: impact of a new algorithm on risk determination (Bergk et al). 2004;76:85-96
- The effect of clarithromycin, fluconazole, and rifabutin on dapsone hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283) (Winter et al). 2004;76:579-87
- The effect of clarithromycin, fluconazole, and rifabutin on sulfamethoxazole hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283) (Winter et al). 2004;76:313-22
- Effect of St John's wort on imatinib mesylate pharmacokinetics (Frye et al). 2004;76:323-9
- Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction (Mai et al). 2004;76:330-40
- Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms (García-Martín et al). 2004;76:119-27
- Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin (Joel et al). 2004;76:45-54
- No adverse hemodynamic interaction between sildenafil and red wine (Leslie et al). 2004;76:365-70
- The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum (van Heeswijk et al). 2004;76:588-97
- A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital (Innocenti et al). 2004;76:490-502
- Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers (Ding et al). 2004;76:73-84

Drug surveillance

- Postmarketing surveillance for drug safety (Holden and Scarazzini) (Letter); (Griffin et al) (Reply). 2004;76:503-5

Drug therapy

- Optimizing drug therapy (Spector) (Letter); (Reidenberg) (Reply). 2004;76:97-8

E

Echinacea purpurea

- In vivo assessment of botanical supplementation on human cytochrome

P450 phenotypes: *Citrus aurantium*, *Echinacea purpurea*, milk thistle, and saw palmetto (Gurley et al). 2004;76:428-40

Electrocardiography

Discovering adverse reactions: why does it take so long? (Woosley). 2004;76:287-9 (Commentary)

QT interval prolongation after oxytocin bolus during surgical induced abortion (Charbit et al). 2004;76:359-64

Enantiomers

Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone (Benmebarek et al). 2004;76:55-63

End stage renal disease; see Kidney failure, chronic

Endothelins

Effects of systemic endothelin A receptor antagonism in various vascular beds in men: in vivo interactions of the major blood pressure-regulating systems and associations with the *GNB3* C825 T polymorphism (Mitchell et al). 2004;76:396-408

Enzymes

Bioequivalence revisited: influence of age and sex on CYP enzymes (Bebia et al). 2004;76:618-27

A novel polymorphism of human *CYP2A6* gene *CYP2A6*17* has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo (Fukani et al). 2004;76:519-27

Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38 (Charasson et al). 2004;76:528-35

Epistasis

Human sympathetic activation by α_2 -adrenergic blockade with yohimbine: bimodal, epistatic influence of cytochrome P450-mediated drug metabolism (Le Corre et al). 2004;76:139-53

Ethics

Publishing work sponsored by the tobacco industry (Stein). 2004;76:517-8 (Commentary)

Ethnic groups

Novel *CYP2C9* genetic variants in Asian subjects and their influence on maintenance warfarin dose (Zhao et al). 2004;76:210-9

Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the *MDR-1*, and *CYP3A4*, and *CYP3A5* genes (Hesselink et al). 2004;76:545-56

F

Felodipine

Bergamottin contribution to the grapefruit juice-felodipine interaction and disposition in humans (Goosen et al). 2004;76:607-17

Fexofenadine

A variant 2677A allele of the *MDR1* gene affects fexofenadine disposition (Yi et al). 2004;76:418-27

Fluconazole

The effect of clarithromycin, fluconazole, and rifabutin on dapsone hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283) (Winter et al). 2004;76:579-87

The effect of clarithromycin, fluconazole, and rifabutin on sulfamethoxazole hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283) (Winter et al). 2004;76:313-22

Fluorouracil

Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin (Joel et al). 2004;76:45-54

Tumor-based pharmacokinetics has greater significance for anticancer drugs than does blood-based pharmacokinetics (Wolf and Present) (Letter). (Joel and Seymour) (Reply). 2004;76:508-9

Flurbiprofen

The effects of metabolic fate of nitroflurbiprofen in healthy volunteers (Zacharowski et al). 2004;76:350-8

Fluvoxamine

Drug interaction of tizanidine and fluvoxamine (Momo et al). 2004;76:509-10 (Letter)

G

Gastric acid

Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status (Sugimoto et al). 2004;76:290-301

Gastric emptying

The effect of sildenafil on gastric emptying in patients with end-stage renal failure and symptoms of gastroparesis (Dishy et al). 2004;76:281-6

Gastroparesis; see Digestive system abnormalities

Gender; see Sex

Genes

Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans (Giessmann et al). 2004;76:192-200

Influence of functional polymorphisms of the *MDR1* gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia (Plasschaert et al). 2004;76:220-9

Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the *MDR-1*, and *CYP3A4*, and *CYP3A5* genes (Hesselink et al). 2004;76:545-56

A variant 2677A allele of the *MDR1* gene affects fexofenadine disposition (Yi et al). 2004;76:418-27

Genetics

Genetic variability in cytochrome P450 3A5 and in vivo cytochrome P450 3A activity: some answers but still questions (Wilkinson). 2004;76:99-103 (Commentary)

Novel *CYP2C9* genetic variants in Asian subjects and their influence on maintenance warfarin dose (Zhao et al). 2004;76:210-9

Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the *MDR-1*, and *CYP3A4*, and *CYP3A5* genes (Hesselink et al). 2004;76:545-56

Genotype

Caution with β_1 -adrenergic receptor genotyping (Lanfear et al) (Letter). (Johnson et al) (Reply). 2004;76:185-6

CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians (Vianna-Jorge et al). 2004;76:18-26

Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status (Sugimoto et al). 2004;76:290-301

Diflomotecan pharmacokinetics in relation to *ABCG2* 421CA genotype (Sparreboom et al). 2004;76:38-44

Effect of the *CYP3A5* genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states (Yu et al). 2004;76:104-12

Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics (Kirchheiner et al). 2004;76:302-12

Pharmacokinetics and *CYP2D6* genotypes do not predict metoprolol adverse events or efficacy in hypertension (Zineh et al). 2004;76:536-44

Glycoproteins

Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans (Giessmann et al). 2004;76:192-200

Grapefruit juice; see Beverages

Gut wall; see Intestines

H

Health

Health risks of herbal remedies: an update (De Smet). 2004;76:1-17

Heart failure, congestive

Influences of sildenafil on lung function and hemodynamics in patients with chronic heart failure (Guazzi et al). 2004;76:371-8

Heart transplantation

Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the *MDR-1*, and *CYP3A4*, and *CYP3A5* genes (Hesselink et al). 2004;76:545-56

Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine (Simonson et al). 2004;76:167-77

Helicobacter pylori

CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of *Helicobacter pylori* (Schwab et al). 2004;76:201-9

Hematopoiesis

Diminishing the risk of nonrelapse mortality in hematopoietic stem cell transplantation: prediction of exposure to the cyclophosphamide metabolite carboxyethylphosphoramide mustard (Qiu et al). 2004;76:270-80

Hemodynamics

Influences of sildenafil on lung function and hemodynamics in patients with chronic heart failure (Guazzi et al). 2004;76:371-8

No adverse hemodynamic interaction between sildenafil and red wine (Leslie et al). 2004;76:365-70

Herbal medicine; see Medicine, herbal

HIV

The effect of clarithromycin, fluconazole, and rifabutin on dapsone hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283) (Winter et al). 2004;76:579-87

The effect of clarithromycin, fluconazole, and rifabutin on sulfamethoxazole hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283) (Winter et al). 2004;76:313-22

Hospital inpatients; see Inpatients

Hydroxylamines

The effect of clarithromycin, fluconazole, and rifabutin on dapsone hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283) (Winter et al). 2004;76:579-87

The effect of clarithromycin, fluconazole, and rifabutin on sulfamethoxazole hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283) (Winter et al). 2004;76:313-22

Hyperforin

Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction (Mai et al). 2004;76:330-40

Hypertension

Effects of systemic endothelin A receptor antagonism in various vascular beds in men: in vivo interactions of the major blood pressure-regulating systems and associations with the *GNB3* C825 T polymorphism (Mitchell et al). 2004;76:396-408

Pharmacokinetics and *CYP2D6* genotypes do not predict metoprolol adverse events or efficacy in hypertension (Zineh et al). 2004;76:536-44

Hypotension

Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism (Granfors et al). 2004;76:598-606

I

Ibuprofen

Interindividual variability in ibuprofen pharmacokinetics is related to in-

teraction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms (García-Martín et al). 2004;76:119-27

Imatinib

Effect of St John's wort on imatinib mesylate pharmacokinetics (Frye et al). 2004;76:323-9

Immunosuppression

Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine (Simonson et al). 2004;76:167-77

Injections, intravenous

Effect of the *CYP3A5* genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states (Yu et al). 2004;76:104-12

Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis (Kharasch et al). 2004;76:452-66

Inpatients

Drug interactions with the potential to prevent prodrug activation as a common source of irrational prescribing in hospital inpatients (Tirkkonen and Laine). 2004;76:639-47

Interactions, drug; see Drug interactions

Intestine, small

Cytochrome P450 3A expression and activity in the human small intestine (Yang et al). 2004;76:391 (Letter)

Intestines

Impact of concentration and rate of intraluminal drug delivery on absorption and gut wall metabolism of verapamil in humans (Glaeser et al). 2004;76:230-8

Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and mitotic effects of methadone (Kharasch et al). 2004;76:250-69

Introns

A novel intronic mutation, 2988GA, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects (Raimundo et al). 2004;76:128-38

Irinotecan

Inhibition of acetylcholinesterase in patients receiving irinotecan (camptothecin-11) (Tobin et al) (Letter); (Blandizzi et al) (Reply). 2004;76:505-8

Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38 (Charasson et al). 2004;76:528-35

A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital (Innocenti et al). 2004;76:490-502

K

Ketoconazole

Ketoconazole, a cytochrome P450 3A4 inhibitor, markedly increases concentrations of levo-acetyl- α -methadol in opioid-naïve individuals (Moody et al). 2004;76:154-66

Kidney failure, chronic

The effect of sildenafil on gastric emptying in patients with end-stage renal failure and symptoms of gastroparesis (Dishy et al). 2004;76:281-6

Kidney transplantation

Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the *MDR-1*, and *CYP3A4*, and *CYP3A5* genes (Hesselink et al). 2004;76:545-56

Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients (Hermann et al). 2004;76:388-91 (Letter)

Kininase II

Angiotensin-converting enzyme inhibition and smoking potentiate the kinin response to cardiopulmonary bypass (Pretorius et al). 2004;76:379-87

Kinins

Angiotensin-converting enzyme inhibition and smoking potentiate the kinin response to cardiopulmonary bypass (Pretorius et al). 2004;76:379-87

L**Lansoprazole**

CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of *Helicobacter pylori* (Schwab et al). 2004;76:201-9

Letters to the editor

Caution with β_1 -adrenergic receptor genotyping (Lanfear et al) (Letter); (Johnson et al) (Reply). 2004;76:185-6
Cytochrome P450 3A expression and activity in the human small intestine (Yang et al). 2004;76:391 (Letter)
Drug interaction of tizanidine and fluvoxamine (Momo et al). 2004;76:509-10 (Letter)
Inhibition of acetylcholinesterase in patients receiving irinotecan (camptothecin-11) (Tobin et al) (Letter); (Blandizzi et al) (Reply). 2004;76:505-8
Optimizing drug therapy (Spector) (Letter); (Reidenberg) (Reply). 2004;76:97-8
Postmarketing surveillance for drug safety (Holden and Scarazzini) (Letter); (Griffin et al) (Reply). 2004;76:503-5
Propofol concentrations during the anhepatic phase of living-related donor liver transplantation (Takizawa et al). 2004;76:648-9 (Letter)
Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients (Hermann et al). 2004;76:388-91 (Letter)
Tumor-based pharmacokinetics has greater significance for anticancer drugs than does blood-based pharmacokinetics (Wolf and Presant) (Letter); (Joel and Seymour) (Reply). 2004;76:508-9

Leukemia, lymphocytic, acute

Influence of functional polymorphisms of the *MDR1* gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia (Plasschaert et al). 2004;76:220-9

Levo-acetyl- α -methadol

Ketoconazole, a cytochrome P450 3A4 inhibitor, markedly increases concentrations of levo-acetyl- α -methadol in opioid-naïve individuals (Moody et al). 2004;76:154-66

Ligands

Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand (Wang et al). 2004;76:628-38

Liver

Cytochrome P450 3A expression and activity in the human small intestine (Yang et al). 2004;76:391 (Letter)
Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis (Kharasch et al). 2004;76:452-66
Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and mitotic effects of methadone (Kharasch et al). 2004;76:250-69

Liver transplantation

Propofol concentrations during the anhepatic phase of living-related donor liver transplantation (Takizawa et al). 2004;76:648-9 (Letter)

Living donors; see Tissue donors**Lung function tests; see Respiratory function tests****M****M8; see Nelfinavir****Males**

Effects of systemic endothelin A receptor antagonism in various vascular beds in men: in vivo interactions of the major blood pressure-regu-

lating systems and associations with the *GNB3* C825 T polymorphism (Mitchell et al). 2004;76:396-408

MDR1* gene; see Genes*Medicine, herbal**

Confusion regarding anticoagulant coumarins in dietary supplements (Booth et al). 2004;76:511-6 (Commentary)
Health risks of herbal remedies: an update (De Smet). 2004;76:1-17

Metabolism

Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism (Granfors et al). 2004;76:598-606
Effect of the *CYP3A5* genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states (Yu et al). 2004;76:104-12
The effects of metabolic fate of nitroflurbiprofen in healthy volunteers (Zacharowski et al). 2004;76:350-8
Human sympathetic activation by α_2 -adrenergic blockade with yohimbine: bimodal, epistatic influence of cytochrome P450-mediated drug metabolism (Le Corre et al). 2004;76:139-53
Impact of concentration and rate of intraluminal drug delivery on absorption and gut wall metabolism of verapamil in humans (Glaeser et al). 2004;76:230-8
Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics (Kirchheiner et al). 2004;76:302-12
Modeling the metabolic effects of terbutaline in β_2 -adrenergic receptor diplotypes (Lima et al). 2004;76:27-37
Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity (Dempsey et al). 2004;76:64-72
Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and mitotic effects of methadone (Kharasch et al). 2004;76:250-69

Methadone

Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone (Benmebarek et al). 2004;76:55-63
Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and mitotic effects of methadone (Kharasch et al). 2004;76:250-69

Metoprolol

Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics (Kirchheiner et al). 2004;76:302-12
Pharmacokinetics and *CYP2D6* genotypes do not predict metoprolol adverse events or efficacy in hypertension (Zineh et al). 2004;76:536-44

Midazolam

Effect of the *CYP3A5* genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states (Yu et al). 2004;76:104-12
In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam (Masica et al). 2004;76:341-9

Milk thistle

In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: *Citrus aurantium*, *Echinacea purpurea*, milk thistle, and saw palmetto (Gurley et al). 2004;76:428-40

Miosis

Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis (Kharasch et al). 2004;76:452-66
Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and mitotic effects of methadone (Kharasch et al). 2004;76:250-69

Mortality

Diminishing the risk of nonrelapse mortality in hematopoietic stem cell transplantation: prediction of exposure to the cyclophosphamide metabolite carboxyethylphosphoramide mustard (Qiu et al). 2004;76:270-80

Multidrug resistance gene; see Genes

Mutation

- A novel intronic mutation, 2988GA, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects (Raimundo et al). 2004;76:128-38

N

Narcotics

- Ketoconazole, a cytochrome P450 3A4 inhibitor, markedly increases concentrations of levo-acetyl- α -methadol in opioid-naïve individuals (Moody et al). 2004;76:154-66

Nelfinavir

- The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum (van Heeswijk et al). 2004;76:588-97

Neoplasm metastasis

- Inhibition of acetylcholinesterase in patients receiving irinotecan (camptothecin-11) (Tobin et al) (Letter); (Blandizzi et al) (Reply). 2004;76:505-8

Neoplasms

- Tumor-based pharmacokinetics has greater significance for anticancer drugs than does blood-based pharmacokinetics (Wolf and Present) (Letter); (Joel and Seymour) (Reply). 2004;76:508-9

Neutropenia

- Mechanism-based models for topotecan-induced neutropenia (Léger et al). 2004;76:567-78

Nicotine

- Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity (Dempsey et al). 2004;76:64-72
A novel polymorphism of human *CYP2A6* gene *CYP2A6*17* has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo (Fukami et al). 2004;76:519-27

Nitric oxide

- The effects of metabolic fate of nitroflurbiprofen in healthy volunteers (Zacharowski et al). 2004;76:350-8
Influences of sildenafil on lung function and hemodynamics in patients with chronic heart failure (Guazzi et al). 2004;76:371-8

Nitroflurbiprofen

- The effects of metabolic fate of nitroflurbiprofen in healthy volunteers (Zacharowski et al). 2004;76:350-8

O

Obituary

- Lewis B. Sheiner, 1940-2004 (Blaschke and Giacomini). 2004;76:650-1

Opioids; see Narcotics

Outpatients

- Population one-compartment pharmacokinetic analysis with missing dosage data (Soy et al). 2004;76:441-51

Oxaliplatin

- Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin (Joel et al). 2004;76:45-54
Tumor-based pharmacokinetics has greater significance for anticancer drugs than does blood-based pharmacokinetics (Wolf and Present) (Letter); (Joel and Seymour) (Reply). 2004;76:508-9

Oxytocin

- Discovering adverse reactions: why does it take so long? (Woosley). 2004;76:287-9 (Commentary)
QT interval prolongation after oxytocin bolus during surgical induced abortion (Charbit et al). 2004;76:359-64

P

Pharmacodynamics

- Age and gender effects on the pharmacokinetics and pharmacodynamics of

triazolam, a cytochrome P450 3A substrate (Greenblatt et al). 2004;76:467-79

CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide (Vormfelde et al). 2004;76:557-66

Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics (Kirchheiner et al). 2004;76:302-12

Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand (Wang et al). 2004;76:628-38

Pharmacogenetics

Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38 (Charasson et al). 2004;76:528-35

Pharmacokinetics

Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate (Greenblatt et al). 2004;76:467-79

CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians (Vianna-Jorge et al). 2004;76:18-26

CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide (Vormfelde et al). 2004;76:557-66

Diflomotecan pharmacokinetics in relation to *ABCG2* 421CA genotype (Sparreboom et al). 2004;76:38-44

Effect of the *CYP3A5* genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states (Yu et al). 2004;76:104-12

Effect of St John's wort on imatinib mesylate pharmacokinetics (Frye et al). 2004;76:323-9

Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone (Benmebarek et al). 2004;76:55-63

Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone (Niemi et al). 2004;76:239-49

Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics (Kirchheiner et al). 2004;76:302-12

Influence of functional polymorphisms of the *MDR1* gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia (Plasschaert et al). 2004;76:220-9

Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms (García-Martín et al). 2004;76:119-27

Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin (Joel et al). 2004;76:45-54

Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand (Wang et al). 2004;76:628-38

Pharmacokinetics and *CYP2D6* genotypes do not predict metoprolol adverse events or efficacy in hypertension (Zineh et al). 2004;76:536-44
The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum (van Heeswijk et al). 2004;76:588-97

Population one-compartment pharmacokinetic analysis with missing dosage data (Soy et al). 2004;76:441-51

Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the *MDR-1*, and *CYP3A4*, and *CYP3A5* genes (Hesseling et al). 2004;76:545-56

Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine (Simonson et al). 2004;76:167-77

Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers (Ding et al). 2004;76:73-84

Tumor-based pharmacokinetics has greater significance for anticancer drugs than does blood-based pharmacokinetics (Wolf and Present) (Letter); (Joel and Seymour) (Reply). 2004;76:508-9

Phenobarbital

A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital (Innocenti et al). 2004;76:490-502

Phenotype

In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: *Citrus aurantium*, *Echinacea purpurea*, milk thistle, and saw palmetto (Gurley et al). 2004;76:428-40

Phenprocoumon

Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status (Schalekamp et al). 2004;76:409-17

Plants, medicinal

Effect of St John's wort on imatinib mesylate pharmacokinetics (Frye et al). 2004;76:323-9

Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction (Mai et al). 2004;76:330-40

In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: *Citrus aurantium*, *Echinacea purpurea*, milk thistle, and saw palmetto (Gurley et al). 2004;76:428-40

Influence of St John's wort on catecholamine turnover and cardiovascular regulation in humans (Schroeder et al). 2004;76:480-9

St John's wort, depression, and catecholamines (Haller). 2004;76:393-5 (Commentary)

Polymorphism

CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide (Vormfelde et al). 2004;76:557-66

CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of *Helicobacter pylori* (Schwab et al). 2004;76:201-9

Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status (Schalekamp et al). 2004;76:409-17

Effects of systemic endothelin A receptor antagonism in various vascular beds in men: in vivo interactions of the major blood pressure-regulating systems and associations with the GNB3 C825 T polymorphism (Mitchell et al). 2004;76:396-408

Functional impact of CYP2C9*5, CYP2C9*6, CYP2C9*8, and CYP2C9*11 in vivo among black Africans (Allabi et al). 2004;76:113-8

Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia (Plasschaert et al). 2004;76:220-9

Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms (García-Martín et al). 2004;76:119-27

A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo (Fukami et al). 2004;76:519-27

Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, and CYP3A4, and CYP3A5 genes (Hesselink et al). 2004;76:545-56

Pregnancy, drug effects

The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum (van Heeswijk et al). 2004;76:588-97

Prescriptions, drug

Drug interactions with the potential to prevent prodrug activation as a common source of irrational prescribing in hospital inpatients (Tirkkonen and Laine). 2004;76:639-47

Primary health care

Drug interactions in primary care: impact of a new algorithm on risk determination (Bergk et al). 2004;76:85-96

Prodrugs

Drug interactions with the potential to prevent prodrug activation as a common source of irrational prescribing in hospital inpatients (Tirkkonen and Laine). 2004;76:639-47

Product surveillance postmarketing

Postmarketing surveillance for drug safety (Holden and Scarazzini) (Letter). (Griffin et al) (Reply). 2004;76:503-5

Prognosis

Optimizing drug therapy (Spector) (Letter); (Reidenberg) (Reply). 2004;76:97-8

Propofol

Propofol concentrations during the anhepatic phase of living-related donor liver transplantation (Takizawa et al). 2004;76:648-9 (Letter)

Proteins

Diffamotecan pharmacokinetics in relation to ABCG2 421CA genotype (Sparreboom et al). 2004;76:38-44

Publishing

Clinical Pharmacology & Therapeutics annual report 2003 (Stein). 2004;76:189-91 (Commentary)

Publishing work sponsored by the tobacco industry (Stein). 2004;76:517-8 (Commentary)

Puerperium

The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum (van Heeswijk et al). 2004;76:588-97

Pupil

Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis (Kharasch et al). 2004;76:452-66

Q

QT interval; see **Electrocardiography**

R**Rabeprazole**

Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status (Sugimoto et al). 2004;76:290-301

Receptors, adrenergic, beta

Modeling the metabolic effects of terbutaline in β_2 -adrenergic receptor diplotypes (Lima et al). 2004;76:27-37

Renal transplantation; see Kidney transplantation**Respiratory function tests**

Influences of sildenafil on lung function and hemodynamics in patients with chronic heart failure (Guazzi et al). 2004;76:371-8

Rifabutin

The effect of clarithromycin, fluconazole, and rifabutin on dapsone hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283) (Winter et al). 2004;76:579-87

The effect of clarithromycin, fluconazole, and rifabutin on sulfamethoxazole hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283) (Winter et al). 2004;76:313-22

Rifampin

Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone (Niemi et al). 2004;76:239-49

Risk factors

Drug interactions in primary care: impact of a new algorithm on risk determination (Bergk et al). 2004;76:85-96

Health risks of herbal remedies: an update (De Smet). 2004;76:1-17

Ritonavir

Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers (Ding et al). 2004;76:73-84

Rosiglitazone

Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone (Niemi et al). 2004;76:239-49

Rosuvastatin

Rosuvastatin pharmacokinetics in heart transplant recipients administered

an antirejection regimen including cyclosporine (Simonson et al). 2004;76:167-77

S

Safety

Postmarketing surveillance for drug safety (Holden and Scarazzini) (Letter); (Griffin et al) (Reply). 2004;76:503-5

St John's wort; see Plants, medicinal

Saw palmetto

In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: *Citrus aurantium*, *Echinacea purpurea*, milk thistle, and saw palmetto (Gurley et al). 2004;76:428-40

Sex

Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate (Greenblatt et al). 2004;76:467-79

Bioequivalence revisited: influence of age and sex on CYP enzymes (Bebia et al). 2004;76:618-27

Sheiner, Lewis B.

Lewis B. Sheiner, 1940-2004 (Blaschke and Giacomini). 2004;76:650-1 (Obituary)

Sildenafil

The effect of sildenafil on gastric emptying in patients with end-stage renal failure and symptoms of gastroparesis (Dishy et al). 2004;76:281-6

Influences of sildenafil on lung function and hemodynamics in patients with chronic heart failure (Guazzi et al). 2004;76:371-8

No adverse hemodynamic interaction between sildenafil and red wine (Leslie et al). 2004;76:365-70

Small intestine; see Intestine, small

Smoking

Angiotensin-converting enzyme inhibition and smoking potentiate the kinin response to cardiopulmonary bypass (Pretorius et al). 2004;76:379-87

Publishing work sponsored by the tobacco industry (Stein). 2004;76:517-8 (Commentary)

Smoking cessation

Time response of cytochrome P450 1A2 activity on cessation of heavy smoking (Faber and Fuhr). 2004;76:178-84

SN-38; see Camptothecin

Stem cell transplantation

Diminishing the risk of nonrelapse mortality in hematopoietic stem cell transplantation: prediction of exposure to the cyclophosphamide metabolite carboxyethylphosphoramide mustard (Qiu et al). 2004;76:270-80

Sulfamethoxazole

The effect of clarithromycin, fluconazole, and rifabutin on sulfamethoxazole hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283) (Winter et al). 2004;76:313-22

Surveillance, drug; see Drug surveillance

Sympathetic nervous system

Human sympathetic activation by α_2 -adrenergic blockade with yohimbine: bimodal, epistatic influence of cytochrome P450-mediated drug metabolism (Le Corre et al). 2004;76:139-53

T

Talinolol

Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans (Giesmann et al). 2004;76:192-200

Tenoxicam

CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians (Vianna-Jorge et al). 2004;76:18-26

Terbutaline

Modeling the metabolic effects of terbutaline in β_2 -adrenergic receptor diplotypes (Lima et al). 2004;76:27-37

Theophylline

Time response of cytochrome P450 1A2 activity on cessation of heavy smoking (Faber and Fuhr). 2004;76:178-84

Therapeutic equivalency

Bioequivalence revisited: influence of age and sex on CYP enzymes (Bebia et al). 2004;76:618-27

Thrombopoietin

Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand (Wang et al). 2004;76:628-38

Time

Time response of cytochrome P450 1A2 activity on cessation of heavy smoking (Faber and Fuhr). 2004;76:178-84

Tissue donors

Propofol concentrations during the anhepatic phase of living-related donor liver transplantation (Takizawa et al). 2004;76:648-9 (Letter)

Tizanidine

Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presynaptic metabolism (Granfors et al). 2004;76:598-606

Drug interaction of tizanidine and fluvoxamine (Momo et al). 2004;76:509-10 (Letter)

Tobacco

Publishing work sponsored by the tobacco industry (Stein). 2004;76:517-8 (Commentary)

Topotecan

Mechanism-based models for topotecan-induced neutropenia (Léger et al). 2004;76:567-78

Torsemide

CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide (Vormfelde et al). 2004;76:557-66

Treatment outcome

CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of *Helicobacter pylori* (Schwab et al). 2004;76:201-9

Triazolam

Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate (Greenblatt et al). 2004;76:467-79

In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam (Masica et al). 2004;76:341-9

Trimethoprim

Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone (Niemi et al). 2004;76:239-49

V

Verapamil

Impact of concentration and rate of intraluminal drug delivery on absorption and gut wall metabolism of verapamil in humans (Glaeser et al). 2004;76:230-8

Vincristine

Influence of functional polymorphisms of the *MDR1* gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia (Plasschaert et al). 2004;76:220-9

W

Warfarin

Novel *CYP2C9* genetic variants in Asian subjects and their influence on maintenance warfarin dose (Zhao et al). 2004;76:210-9

White subjects

CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of *Helicobacter pylori* (Schwab et al). 2004;76:201-9

A novel intronic mutation, 2988GA, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects (Raimundo et al). 2004;76:128-38

Wine

No adverse hemodynamic interaction between sildenafil and red wine (Leslie et al). 2004;76:365-70

Y

Yohimbine

Human sympathetic activation by α_2 -adrenergic blockade with yohimbine: bimodal, epistatic influence of cytochrome P450-mediated drug metabolism (Le Corre et al). 2004;76:139-53

